Cryolife (CRY) Receiving Somewhat Positive Media Coverage, Report Finds

News articles about Cryolife (NYSE:CRY) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cryolife earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.7237483532172 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

CRY opened at $20.05 on Monday. The company has a market cap of $670.82, a PE ratio of 50.13 and a beta of 0.73. The company has a current ratio of 4.18, a quick ratio of 3.09 and a debt-to-equity ratio of 0.81. Cryolife has a 1 year low of $14.02 and a 1 year high of $24.00.

How to Become a New Pot Stock Millionaire

Cryolife (NYSE:CRY) last released its quarterly earnings data on Wednesday, March 7th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.11. The business had revenue of $52.80 million for the quarter, compared to analysts’ expectations of $48.40 million. Cryolife had a return on equity of 5.93% and a net margin of 1.95%. Cryolife’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.09 earnings per share. research analysts predict that Cryolife will post 0.09 earnings per share for the current year.

Several research analysts have commented on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $28.00 price target (up from $25.00) on shares of Cryolife in a research report on Friday, March 9th. Northland Securities reaffirmed a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research report on Thursday, March 8th. Zacks Investment Research raised Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, ValuEngine downgraded Cryolife from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Three analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $25.83.

In other news, Director C Elkins Ronald sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $22.00, for a total transaction of $44,000.00. Following the sale, the director now directly owns 97,849 shares in the company, valued at $2,152,678. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cryolife (CRY) Receiving Somewhat Positive Media Coverage, Report Finds” was originally posted by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with's FREE daily email newsletter.

Leave a Reply